A Phase II Clinical Trial of Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-del (5q) MDS Patients.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Sep 2017
At a glance
- Drugs Lenalidomide (Primary) ; Prednisone (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 16 Sep 2017 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
- 17 Mar 2017 Planned End Date changed from 1 May 2017 to 1 Dec 2017.
- 25 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 May 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History